MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
NCT03552536
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
5
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV-1 Infection
Interventions
DRUG:
MK-8583
Sponsor
Merck Sharp & Dohme LLC